SEC Form 4 · accession 0001171843-17-005225
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David M Goldenberg
Officer — See Remarks · Director
Period of report
Aug 21, 2017
Accepted (ET)
Aug 23, 2017 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F4 | Aug 21, 2017 | S | 20,000 | $8.9713 | D | 3,475,578 | I | See Footnote |
| Common StockF4 | Aug 22, 2017 | S | 10,000 | $9.50 | D | 3,465,578 | I | See Footnote |
| Common StockF4 | Aug 23, 2017 | S | 10,000 | $9.50 | D | 3,455,578 | I | See Footnote |
| Common StockF1 | holding | — | — | — | 2,410,489 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes a total of 635,935 shares held as joint tenants by the reporting person and his spouse, Ms. Cynthia L. Goldenberg, also known as Cynthia L. Sullivan, a director of the Company.
- F2The price in column 4 is a weighted average price. The prices actually received in this transaction range from $8.85 to $9.09.
- F3The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
- F4Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.
Remarks
Chief Scientific Officer and Chief Patent Officer